Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (3 ops.)
Latest filing published 17 Aug 2026 for 10x Genomics, Inc., €262k. Read the official filing
Filing timeline
BuySaleSarah A. Teichmann
Insider track record
Disclosed buys
0
Disclosed sells
3
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
Sarah A. Teichmann: trading record in brief
Sarah A. Teichmann discloses dealings in 10x Genomics, Inc. to SEC (Form 4). In total, 6 filings cover trades dated from 30 August 2024 to 14 August 2026.
Sales make up the whole of the open-market record (3 sales, €500k). Other entries cover 3 share grants. In 2026 alone, the filings show no purchases and 3 sales.
On 17 August 2026 came the latest disclosure, an open-market sale for €262k in 10x Genomics, Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Sarah A. Teichmann
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations6 total
5,278 shares@ US$57.29Class A Common StockSEC:0001610717-26-000359:0
2,273 shares@ US$57.15Class A Common StockSEC:0001610717-26-000359:1
8,829 shares0Class A Common StockSEC:0001610717-26-000196:0
7,579 shares@ US$19.41100.0% of flowClass A Common StockSEC:0001610717-26-000074:0
15,357 shares0Class A Common StockSEC:0001610717-25-000172:0
19,002 shares0Class A Common StockSEC:0001610717-24-000461:0
6 of 6 declarations
